References
- Chapman R. Prevention and treatment of candida infection in neonates. Semin Perinatol 2007;31:39-46 https://doi.org/10.1053/j.semperi.2007.01.006
- Noyola DE, Fernandez M, Moylett EH, Baker CJ. Ophthalmologic, visceral, and cardiac involvement in neonates with candidemia. Clin Infect Dis 2001;32:1018-23 https://doi.org/10.1086/319601
- Natarajan G, Lulic-Botica M. Experience with caspofungin in the treatment of persistent fungemia in neonates. J Perinatol 2005;25:770-7 https://doi.org/10.1038/sj.jp.7211380
- Smith PB, Steinbach WJ, Cotten CM. Caspofungin for the treatment of azole resistant candidemia in a premature infant. J Perinatol 2007;27:127-9 https://doi.org/10.1038/sj.jp.7211637
- Wey SB, Motomi M, Pfaller MA, Woolson RF, Wenzel RP. Risk factor for hospital acquired candidemia: a matched casecontrol study. Arch Intern Med 1989;149:2349-53 https://doi.org/10.1001/archinte.149.10.2349
- Stamos JK, Rowley AH. Candidemia in a pediatric population. Clin Infect Dis 1995;20:571-5
- Komshian SV, Uwaydah AK, Sobel JD, Crane LR. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patients: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 1989;11:379-90 https://doi.org/10.1093/clinids/11.3.379
- Bross J, Talbot GH, Maislin G, Hurwitz S, Storm BL. Risk factors for nosocomial candidemia: a case control study in adults without leukemia. Am J Med 1989;87:614-20 https://doi.org/10.1016/S0002-9343(89)80392-4
- Wey SB, Motomi M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 1998;148:2642-7 https://doi.org/10.1001/archinte.148.12.2642
- Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am J Med 1991;91(3B):72S-75S
- Arathoon EG. Clinical efficacy of echinocandin antifungals. Curr Opin Infect Dis 2001;14:685-91
- Walsh TJ, Hiemenz JW, Seibel NL. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26:1383-96 https://doi.org/10.1086/516353
- Denning DW. Echinocandin antifungal drugs. Lancet 2003;362:1142-51 https://doi.org/10.1016/S0140-6736(03)14472-8
- Tawawa S, Ikeda F, Maki K, Morishita Y, Otomo K, Teratani N, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicro Agents Chemother 2000;44:57-62 https://doi.org/10.1128/AAC.44.1.57-62.2000
- Keating GM, Jarvis B. Caspofungin. Drugs 2001;61:1121-9 https://doi.org/10.2165/00003495-200161080-00007
- Kartsonis N, Killar J, Mixson L, Hoe CM, Sable C, Bartizal K. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: Relationship of MIC to treatment Outcome. Antimicrob Agents Chemother 2005;49;3616-23 https://doi.org/10.1128/AAC.49.9.3616-3623.2005
- Villanueva A, Gotuzzo E, Arathoon EG. A randomized double- blind study of caspofugin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001;33:1529-35 https://doi.org/10.1086/323401
- Odio CM, Araya R, Pinto LE, Castro CE, Vasquez S, Alfro B, et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J 2004;23:1093-7
- Yalaz M, Akisu M, Hilmioglu S, Calkavur S, Cakmak B, Kultursay N, et al. Successful caspofungin treatment of multidrug resistant Candida parapsilosis septicaemia in an extremely low birth weight neonate. Mycoses 2006;49:242-5 https://doi.org/10.1111/j.1439-0507.2006.01220.x
- Walsh TJ, Adamson PC, Seibel NL, Flynn PM, Neely MN, Schwartz C, et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005;49:4536-45 https://doi.org/10.1128/AAC.49.11.4536-4545.2005
- Steinbach WJ, Benjamin DK. New antifungal agents under development in children and neonates. Curr Opin Infect Dis 2005;18:484-9 https://doi.org/10.1097/01.qco.0000185986.64759.9a
- Clancy CJ, Nguyen MH. Correlation between in vitro susceptibility determined by E test and response to therapy with amphotericin B: results from multicenter prospective study of candidemia. Antimicrob Agents Chemother 1999;43:1289-90
Cited by
- Candidose congénitale systémique, forme rare de candidose néonatale : à propos d’une observation chez un nouveau-né prématuré vol.18, pp.3, 2010, https://doi.org/10.1016/j.arcped.2010.12.017